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Abstract Cancer stem cell (CSC) markers have attracted con-
siderable attention in tumor diagnostic, prognostic, and therapeu-
tic implications. Detection of cancer stem cells in circulating
blood using cancer stem cell markers has received remarkable
attention recently. In this study, we aimed to investigate the mes-
senger RNA (mRNA) expression level of Lgr5 and DCLK1 as
most proposed colorectal CSC markers in blood circulation also
determine the subsequent association to patients’ clinical and
pathological findings. Peripheral blood mononuclear cells
(PBMCs) of 58 patients with colorectal cancer at stage I–IV with
33 out of 58 patients undergoing preoperative chemoradiothera-
py (CRT), as well as 58 healthy controls have been isolated and
the extracted RNAs were analyzed using real-time PCR. The
mRNA expression pattern of CSC markers of patients and con-
trols was compared using ΔΔCt method. The expression level
of Lgr5 was significantly higher in colorectal cancer (CRC)
patients comparing to healthy group (4.8-fold change,
p<0.001). Also there was a significant increase in expression
level of Lgr5 in patients at stages III and IV comparing to stages
I and II (p=0.031) and higher grades (p=0.039) of CRC. The
expression of DCLK1 was also elevated in patients significantly
(2.7-fold change, p<0.001) and the related expression was in-
creased by increasing disease stage (p=0.025). Combination of
DCLK1 and Lgr5 markers was analyzed by logistic regression
and proved to be a slightly better marker compared to each
marker alone. Interestingly the DCLK1 expression level was
significantly higher in patients undergoing preoperative CRT
(p=0.041); however, no association to neoadjuvant CRT was
observed for Lgr5. Considering the over-expression of DCLK1
and Lgr5 in circulating blood of CRC patients comparing to
controls, our results might emphasize on the presence of CSCs
in blood of these patients which might be attributed to their
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clinical and pathological characteristics and may lead to apply in
future clinical implications. Moreover, the higher expression lev-
el of DCLK1 in patients undergoing CRT can propose it as a
more relevant candidate among CSCmarkers comparing to Lgr5
for CRC patients.
Keywords Colorectal cancer . Cancer stem cell .
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Introduction
Colorectal cancer (CRC) is the third cause of cancer-related
death in the world [1], and patients who undergo curative re-
section are at a high risk of developing local or metastatic re-
currence later in their life [2]. In spite of several available diag-
nostic procedures for early detection and monitoring of CRC
including fecal occult blood test (FOBT) and carcinoembryonic
antigen (CEA), finding more reliable, sensitive, and specific
markers is still considered as a primary concern for prognostic
and diagnostic purposes [3]. Recently, a great deal of investi-
gations has focused on cancer stem cell (CSC) and its markers
in tumor diagnosis, monitoring, and therapy [4–6]. According
to CSC hypothesis, a minority population of cancer cells de-
fined as CSCs is responsible for tumor initiation, metastasis,
recurrence, and drug resistance [7–11], suggesting that applica-
tion of CSC markers is a more efficient strategy for diagnosis,
monitoring, and treatment of tumors.
CSCs, like normal stem cells, are characterized by their ca-
pability of asymmetric division to make more stem cells and
symmetric division to generate rapidly differentiating cells. In
other description, CSC population consists of a mixture of two
phenotypes: a proliferative and a quiescent type resulting from
symmetric and asymmetric cell divisions, respectively [12].
Many recent studies suggest that quiescent CSCs are more in-
vasive CSCs which play the main role in tumor invasiveness,
while proliferating CSCs are the main players of tumor bulk
formation through uncontrolled symmetric division leading to
more proliferating tumor cell population [13–16]. Given the
fact that radiotherapy and chemotherapy affect dividing cells,
quiescent CSCs resist chemoradiotherapy (CRT) and cause tu-
mor recurrence, sometimes many years later [17–20]. As a
result, accepting cancer stem cell concept demands reevaluation
and redirection of cancer therapy and diagnosis in order to
concentrate our approach on tumor stem cell as a tumor root
instead of tumor differentiating cell as tumor foliage.
CSCs have been isolated from several tumors including
breast [21], brain [22], prostate [23], pancreas [24], liver [25],
and lung [26]. Moreover, many of potential markers including
CD133 [27–29], CD44 [29], CD166 [29], and CD24 [27, 30]
have been frequently reported as colorectal CSC markers. Al-
though commonality of normal tissue stem cell markers and
cancer stem cell markers has always been a controversial
challenge in application of CSC markers for clinical implica-
tions [31], Nakanishi et al. focused on this drawback and dem-
onstrated that specific tumor stem cell markers are remained to
be unraveled [32]. Their investigation revealed that
doublecortin-like kinase 1 (DCLk1), a member of doublecortin
family (Dcx) which encodes several microtubule-associated
proteins (MAPs) [33], distinguishes between tumor and normal
stem cells in the intestine. MAPs bind to microtubules and
stabilize them [34], therefore helping cell division. Since the
life of tumor depends on continuous proliferation of tumor
cells, it can be postulated that MAPs are probably involved in
tumor progression [35]. In this regard, targeting a MAP that is
expressed specifically in cancer stem cells and not in normal
stem cells could be the missing key of tumor diagnosis, moni-
toring, and therapy. Nakanishi and his colleagues also sug-
gested that DCLK1 and other CSC markers of CRC named
leucine-rich repeat-containing G protein-coupled receptor 5
(Lgr5) are expressed simultaneously, and they further showed
that DCLK1+/Lgr5+ cells have the potential to be considered as
CSC of colorectal cancer. Lgr5 also known as G protein-
coupled receptor 49 (GPR49) has been recently notified as a
marker of intestinal stem cell [36] and CSC [37–39].
Accumulating evidences suggest that CSC is the main sub-
population involved in invasive properties of tumors such as
metastasis [40]. Based on the classical metastasis simplifica-
tion, an orderly sequence of steps, including local invasion,
intravasation, survival in the blood circulation, extravasation,
and colonization in new organ, is expected in order to com-
plete the metastatic cascade [41, 42]. Assuming CSCs as the
most qualified cells to form metastasis, tracing them in the
blood circulation step would be a valuable consideration.
Based on these findings, we hypothesized that DCLK1and
Lgr5 expression in peripheral blood (PB) might reflect the pres-
ence of circulating stem cells in CRC. Thus, we aimed to trace
these markers in blood sample of CRC patients to elucidate the
probable potency of these two genes as potential CSC markers.
Since DCLK1 and Lgr5 are frequently cited to be the most
potential CSC markers in CRC [43–46], a reasonable correla-
tion between the expression of DCLK1 and Lgr5 in blood
circulation is expected.
In consequence, our study focused on the evaluation of
DCLK1 and Lgr5 expression in the PB of colorectal cancer
patients using quantitative real-time reverse transcription po-
lymerase chain reaction (qRT-PCR). First, we aimed to find
out whether these markers are detectable in blood samples of
CRC patients which may further apply in diagnostic or prog-
nostic settings. Second, we explored the existence of reason-
able correlation between the expression patterns of these
two markers and clarified whether they are attributed to
patient’s clinicopathological characteristics. Possible as-
sociations between these two markers were assessed in
order to find whether their combination may lead to the
more efficient marker.
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To our knowledge, this is the first study that is exploring
the expression level of DCLK1 as a potential CSC marker in
the PB of CRC patients and revealing its association to Lgr5
as another proposed CSC marker of colorectal cancer.
Materials and methods
Patients
A total number of 58 CRC patients, 34 with colon and 24 with
rectum cancer, from surgery department of Imam Khomeini
Hospital of Tehran University of Medical Sciences were in-
cluded in this study. The patients’ clinical characteristics are
shown in details in Table 1.
Tumors were staged and graded according to TNM classi-
fication [47], and 11 patients were at stages I and II, 28 cases
were at stage III, and 19 patients were at stage IV of
adenocarcinoma.
The same number of control samples was taken from pa-
tients or persons who were referred to hospital for other rea-
sons with the exception of any kind of cancer. Controls with
the history of any kind of tumor were excluded from the study.
Controls’ age and sex distribution was considered to be com-
parable to the patients. The mean age of patients and controls
was 64.6 and 63.8, respectively.
Considering the fact that preoperative CRTcan have positive
effect on tumor control and morbidity reduction in locally ad-
vanced tumors [48, 49], neoadjuvant CRT were administered
for stages II to IV based on the protocol proposed by a German
rectal cancer study group [49]. The main neoadjuvant chemo-
therapy regimen consisted of intravenously infusion of a dose
of 1000mg/m2/day of 5-fluorouracil (5-FU) during the first and
fifth weeks of radiotherapy. The concurrent preoperative radio-
therapy protocol included the administration of a total dose of
50 GYwhich was given in 25 fractions during 5 weeks. Totally,
33 out of 58 patients were preoperatively CRT treated.
This study was approved by the Ethics Committee of clin-
ical investigation of Tehran university of Medical Sciences,
and written informed consents were obtained from all patients
and controls.
Samples A total of 10 ml blood sample was withdrawn in
EDTA tubes (BDVacutainer™ Plastic BloodCollection Tubes)
before surgical operation and maintained at room temperature
and processed with Ficoll within a maximum of 1 h after col-
lection. Isolated peripheral blood mononuclear cells (PBMCs)
were stored at −80 °C until later examinations. Before storing at
−80, PBMCs were counted using a hemocytometer and a con-
centration of 6000 cells per μl were prepared in order to min-
imize the cell count differences between samples.
RNA extraction, cDNA synthesis, and primer design
Of the prepared PBMC, 100 μl was directly used in RNA
extraction process. After RNA extraction using TRIzol reagent
and DNase treatment of extracted RNA, complementary DNA
(cDNA) was synthesized using Revert Aid First Strand cDNA
Synthesis Kit according to the instructions (Thermo Scientific,
USA). Real-time PCR was performed using SYBR® Premix
Ex Taq™ II (Takara, Japan). Beta-actin was selected as refer-
ence gene and its primers were purchased from Qiagen Com-
pany (Hs_Actb_1_SG,QuantiTect Primer AssayQT00095431,
Qiagen, USA). DCLK1 and Lgr5 primers were designed with
AlleleID 6.0 software and were synthesized byMetabion Com-
pany (Germany). Their sequences are as follows:
DCLK1 F: AGGGTCGTAAACTGGTGGGAAAC
DCLK1 R: TGTCTGTATGGGCAAGATATGGTAAAC
and
Lgr5 F: CTGAACTAAGAACACTGACTCTGAATG
Lgr5 R: CACTTGGAGATTAGGTAACTGATTGC
Real-time PCR
Real-time PCR was performed on a StepOnePlus™ Real-
Time PCR System (Applied Biosystems, USA) for 1 cycle
at 95 °C for 2 min followed by 40 cycles at 95 °C for 5 s
Table 1 Patients’ clinicopathologic characteristics
Parameter Groups Number Percent
Age (years) 20 to 40 9 15.5
40 to 60 23 39.7
≥60 26 44.8
Gender Female 27 46.5
Male 31 53.5
Tumor location Colon 34 58.6
Rectum 24 41.4
TNM stage I and II 11 19
III 28 48.3
IV 19 32.7
Grade Low 16 27.5
High 43 72.5
Number of metastatic sites 0 39 67.2
1 14 24.2
≥2 5 8.6
Lymphatic invasion Unknown 7 12.1
No 16 27.5
Yes 35 60.4
Neoadjuvant history Yes 33 56.9
No 25 43.1
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and 60 °C for 30 s. Specificity of products was verified by
melting curve analysis (Fig. 1). Notably, each assay was done
in triplicate and positive and negative controls were included
in each run. Data was analyzed using comparative Ct method
[50]. Also 2−ΔCt where ΔCt is (CT gene of interest−CT in-
ternal control) was calculated in order to obtain mean±SD of
each sample for further statistical analysis. Since the basic
assumption of comparative Ct method is the approximately
equal amplification efficiency of target and reference genes,
average efficiency of each gene was calculated using real-time
PCR Miner [51]. Conducting the experiment, comparable ef-
ficiency of β-actin (95.7), DCLK1 (94.8), and Lgr5 (96.6)
approved the comparative Ct method for quantitative evalua-
tion of DCLK1 and Lgr5 messenger RNA (mRNA) levels.
Study design and statistical analysis
Based on a designed prospective diagnostic case-control
study, the main purpose of our study was to evaluate the
mRNA expression level of Lgr5 and DCLK1 in isolated
PBMC from CRC patients comparing to controls and further
delineate the association of biomarkers expression level with
patients’ clinical and pathological features. In support of this,
ΔΔCt was applied to get a fold change of gene expression
level among patients and controls and parametric tests were
used to assess the probable correlation between mRNA ex-
pression level of markers and clinicopathological characteris-
tics. The correlation between Lgr5 and DCLK1was measured
by Pearson correlation coefficient test.
Based on our aims, the diagnostic performance of Lgr5 and
DCLK1 as PB tumor markers was estimated by plotting re-
ceiver operating characteristic (ROC) curves and calculating
area under the curve (AUC). Maximum point of Youden index
was taken as an optimal cutoff of mRNA expression level
separating case and control groups. Binary logistic regression
was used to assess the diagnostic suitability of both markers
together. IBM SPSS Statistics 22 was used for statistical
analysis and a p value of <0.05 was considered statistically
significant.
Results
The mean and standard deviation (SD) of Lgr5 and DCLK1
mRNA level in PB of CRC patients and controls was calcu-
lated using 2−ΔCt, as previously mentioned, and the related
fold changes was obtained. In order to facilitate the calcula-
tion, decimals up to five digits have been removed. Based on
our analysis, the mean of Lgr5 mRNA expression level was
363.2 (SD=115.1) in CRC patients and 75.3 (SD=33.6) in
controls (Fig. 2). As a result, a 4.8-fold increase in the expres-
sion level of Lgr5 in blood of CRC patients was observed
comparing to controls that was statistically significant
(p<0.001). Additionally, Lgr5 expression level was signifi-
cantly higher in patients at stages III and IV comparing to
stages I and II (p=0.031). The significant elevation in Lgr5
expression level was also seen in high-grade tumors (p=
0.039). CRT status had no significant effect on the expression
of Lgr5 in PB of CRC patients. In addition, there was no
significant correlation between the expression level of Lgr5
and other clinicopathologic findings (Table 2).
The mean of DCLK1 expression level in PB was 19.1
(SD=10.3) in CRC patients and 7.1 (SD=4.6) in controls
(Fig. 2). Accordingly, DCLK1mRNA level showed a 2.7-fold
increase in PB of CRC patients compared to controls
(p<0.001). DCLK1 mRNA level was significantly higher in
stages III and IV compared to stages I and II (p=0.025). More-
over, a significant correlation was observed comparing the
DCLK1 expression level in patients with and without the his-
tory of neoadjuvant therapy. Further analysis proved that
DCLK1 was upregulated in patients with the history of neo-
adjuvant therapy (p=0.041). All statistical analysis is summa-
rized in Table 2 based on calculated p value.
Fig. 1 DCLK1 melt curve
analysis
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Diagnostic test evaluation was considered based on sensi-
tivity and specificity by constructing receiver operating char-
acteristic (ROC) curve and further calculating area under the
curve (AUC). The optimal cutoff for mRNA expression level
that separate CRC patients from control was also determined.
Comparing expression level of Lgr5 in patients and controls,
the AUC was 0.865 (95 % CI, 0.783–0.925; p=0.001)
(Fig. 3). In accordance to Lgr5 expression level, the optimal
cutoff value (Youden index) was defined as 145.6 and the
sensitivity and specificity of 74.2 and 90.5 were achieved,
respectively.
As for DCLK1, the ROC curve showed an AUC of 0.748
(95%CI, 0652–0830; p=0.001) (Fig. 3). The DCLK1mRNA
level of 4.7 was defined as cutoff point and the sensitivity and
specificity of 81 and 58, respectively, was determined in the
mentioned cutoff value.
Combination of DCLK1 and Lgr5 markers was analyzed
by logistic regression and predicted probabilities of diagnosis
were used to generate a Bcombination marker^ ROC curve.
The combination (DCLK1/Lgr5) had an AUC=0.885 (95 %
CI, 0.817–0.947; p=0.001) (Fig. 3). The sensitivity and spec-
ificity of the combination were 78 and 90, respectively. Con-
sequently, combination marker may act more efficiently com-
paring to each single marker.
Correlation analysis was assessed using Pearson’s correla-
tion coefficient test in order to determine the association of
Lgr5 and DCLK1 values. The results showed a weak positive
correlation of 0.305 that was statistically significant (95 % CI,
0.1159–0.4734; p=0.002).
Discussion
Following the emergence of CSC hypothesis and its potential
roles in tumor progression, metastasis, recurrence, and resis-
tance to treatment, many efforts have been devoted to explore
the implication of CSCs in prediction, prognosis, and treat-
ment of various kinds of tumors including colorectal cancer
[4]. A more recent interest has focused on circulating CSC
(CCSC) markers based on the fact that PB is a suitable sample
for investigating tumor markers as it benefits from
noninvasiveness, simplicity of sampling, and affordability
[52, 53]. Iinuma et al. investigated the mRNA expression level
of CD133 as a proposed CSC marker in PB of CRC patients
and reported it as a significant prognostic marker in patients
with Dukes’ B and C of colorectal cancer [54]. Fan et al.
investigated prognostic significance of CD45−/CD90+
Fig. 2 qRT-PCR analysis of DCLK1 and Lgr5 mRNA expression level in CRC patients compared to healthy controls. Data are shown as mean±SD
Table 2 Correlation of clinicopathologic findings with Lgr5 and
DCLK1 expression showed by p value
Parameter Groups Lgr5 DCLK1
Age (years) 20 to 40 0.42 0.10
40 to 60
≥60
Gender Female 0.32 0.36
Male
Tumor location Colon 0.23 0.12
Rectum
TNM stage I and II 0.031 0.025
III and IV
Grade Low 0.039 0.06
High
Number of metastatic sites 0 0.14 0.09
1
≥2
Lymphatic invasion Unknown 0.21 0.08
No
Yes
Neoadjuvant history Yes 0.18 0.041
No
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subpopulation as a potential CCSC marker in PB of patient
suffering from hepatocellular carcinoma (HCC) and revealed
that patients with CCSC ≤0.01 % showed significantly more
favorable prognosis than those with CCSC >0.01 % [55].
Pilati et al. studied the prognostic value of putative circulating
cancer stem cells in patients undergoing hepatic resection for
colorectal liver metastasis and concluded that CD133+ CTC
may emerge as a suitable prognostic marker to stratify the risk
of these patients [56]. The correlation between Lgr5 expres-
sion level and clinicopathological features as well as clinical
outcome of CRC patients has been discussed in depth
throughout the literature [37–39]. In addition, the diagnostic
and prognostic significance of circulating Lgr5 as a potential
marker of CRC in PB has been recently reported [57]. More-
over, accumulating evidences have emphasized on the role of
DCLK1 as a candidate of CSC markers in CRC patients [44,
45]. To our knowledge, this is the first study investigating
DCLK1 mRNA expression level in blood circulation of
CRC patients. In addition, this would be the first study com-
paring the expression pattern of DCLK1 and Lgr5, as the most
Fig. 3 Separate and combined Lgr5 and DCLK1 ROC curves. Area under the curve, 95 % confidence interval, and p values are shown
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remarkable CSC markers of CRC, in PB. Regarding DCLK1
as a marker of colorectal tumor stem cell and not normal
intestinal stem cell, comparing the expression pattern of it to
Lgr5 as a maker of both normal and cancerous intestinal stem
cell marker [32] might give rise to valuable information that
may possibly help future therapeutic and diagnostic implica-
tions of CSCs of colorectal cancer.
Our finding confirmed the previous studies indicating
higher expression level of Lgr5 in PB of CRC patients com-
pared to control group [57]. We also confirmed that Lgr5
expression was significantly higher in higher stages of CRC.
Based on previous histological analysis [43], over-
expression of DCLK1 in PB of CRC patients was expected
accordingly. As expected, our result showed a significant in-
crease in DCLK1 mRNA level in PB of CRC patients com-
pared to PB of controls. In addition, analyzing of samples
based on the history of neoadjuvant therapy showed a signif-
icant increase in DCLK1 expression in patients with preoper-
ative CRT history. Despite of many evidences indicating the
relevance of Lgr5 expression pattern to tumor characteristics
such as stage, prognosis, and survival [57, 58], the specific
expression pattern of DCLK1 in neoadjuvant CRT-treated pa-
tients is perfectly suited to the concept of CSC. As previously
discussed, dividing tumor cells are influenced by CRT and
quiescent CSCs are resistant to such kind of therapeutic agents
[17–20]. Regarding DCLK1 as a CSC marker that distin-
guishes CRC stem cell from normal stem cell, it could be
concluded that CRT is unable to eliminate tumor cells contain-
ing DCLK1 marker. Consequently, in such patients, local and
circulating tumor cells (CTCs), a combination of differentiat-
ed tumor cells, dividing tumor cells, and cancer stem cells
would likely be enriched with CSCs. In other word, prior to
CRT, tumor mass consists of a rare subgroup of CSC among a
huge group of dividing tumor cells, whereas after CRT, the
majority of dividing tumor cells has been eliminated by CRT,
leading to CSC enrichment in both tumor tissue and blood
circulation of CRC patients. Such phenomenon has been re-
ported in several similar studies with different markers. Ham-
ilton and Olszewski’s study revealed the chemotherapy-
induced enrichment of CSC in lung cancer [59]. Abubaker
et al. showed an increased tumor burden as a result of single
treatment of chemotherapy leading to the enrichment of
ovarian cancer stem-like cells [60]. Dylla et al. reported
colorectal cancer stem cell enrichment in xenogeneic
tumors following chemotherapy [19]. Indeed, enrichment
of CSCs in response to CRT is evidence that highlights
CSC’s clinical relevance. Likewise, the independency of
Lgr5 expression pattern to CRT situation of patients
may attenuate its proposed role as a potential CSC
marker in CRC patients.
It is worth noting that since advanced tumors are more
metastatic, more CSC will subsequently enter into blood cir-
culation of patients with higher stages of the disease, and our
study confirmed that the expression level of DCLK1 is elevat-
ed by increasing in the stages of CRC.
Although CSC enrichment following CRT may justify
DCLK1 over-expression in CRT-treated patients, it should
be noticed that over/under-expression of CSC marker is a
multifactorial process. According to a great body of evi-
dences, CSC fate is controlled by lots of complex functions
such as epigenetic alterations including DNAmethylation and
histone modifications [61]. Several miRNAs cooperate with
DNA methylation to regulate the balance between self-
renewal and differentiation of CSCs [62]. Multiple observa-
tions indicate that maintenance of CSC features is orchestrated
by these mechanisms leading to switching CSC markers on
and off to generate heterogeneous CSCs with distinct pheno-
types [61]. As a result, CSC phenotype may change in differ-
ent phases of tumor in order to sustain tumor survival and
growth and continuous alterations in CSC markers seems to
be a programmed phenomenon. Consequently, although CRT
did not show a significant effect on Lgr5 expression pattern,
the probable role of Lgr5 as a potential CSC in CRC cannot be
ignored and further investigations are still required to eluci-
date the different effects of CRT on DCLK1 and Lgr5 expres-
sion pattern.
The viewpoint that CSCs might switch their markers on
and off will lead to a heterogeneous CSC population that
makes the use of CSCmarkers more difficult. However, using
a combination of CSC markers may solve the problem to
some extent. Accepting this theory may explain why the
DCLK1 and Lgr5 combination makes a slightly better marker,
and it may even get better if we add some more CSC markers
to this combination.
Other explanations for up/down-regulation of CSC
markers are still remaining. For example, tumor cell dissemi-
nation and metastasis is dependent on epithelial-mesenchymal
transition (EMT) process which converts adherent epithelial
cells into migratory cells [63]. An increase in the proportion of
immortalized human mammary epithelial cells exhibiting
CSC markers was observed after EMT induction [64]. More-
over, emerging evidence suggests that resistance to chemo-
therapy is associated with acquiring CSC and EMT features
[65]. In this regard, pancreatic cell lines that exhibited EMT
features were resistant to chemotherapy agents and pancreatic
cancer cells that were selected to be resistant to gemcitabine
have exhibited EMT markers and increased invasion capabil-
ities [66]. In other word, chemotherapy may affect the expres-
sion of some CSC markers such as DCLK1, while it may not
affect other markers such as Lgr5. In addition, considering the
effect of EMT on CSC, there might be a difference between
local and circulating CSC markers and local CSC markers
may not necessarily act as circulating CSC marker.
To further complicate the matter, Vedeld et al. surveyed a
new aspect of DCLK1expression. Their study demonstrated
that the DCLK1 promoter is hypermethylated in CRC patients
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which results in down-regulation of DCLK1 in CRC patients,
while no methylation has occurred in the normal mucosa sam-
ples [67]. However, chemotherapy situation of patients was
not considered in their study; therefore, up-regulation of
DCLK1 in patients who have undergone neoadjuvant therapy
cannot be rejected by this data.
As previously mentioned, based on CSC concept, CSCs
are the main tumor subpopulation responsible for CRT resis-
tance. As such, a number of resistance strategies, including
ATP-binding cassette (ABC) transporter expression, aldehyde
dehydrogenase (ALDH) activity, B cell lymphoma-2 (BCL-
2)-related chemoresistance, enhanced DNA damage response,
and activation of signaling pathways, have been recognized
for CSC drug resistance [17]. As a result, DCLK1 over-
expression in chemoradiotherapy-treated CRC patients may
be explained by CSC chemoradioresistance strategies leading
to a new CSC clonal expansion resistant to CRT and methyl-
ation with higher DCLK1 expression.
Finally, even with all listed possibilities leading to different
effects of CRTon Lgr5 and DCLK1, it could be simply related
to the fact that DCLK1 only marks colorectal CSCs while
Lgr5 is supposed to mark both colorectal normal and cancer
stem cells, and the interaction between CRT and normal stem
cells may affect Lgr5 expression pattern.
It is noteworthy that in both our study and Vedeld’s study,
the DCLK1 mRNA rather than DCLK1 protein has been in-
vestigated. Although mRNA and protein reasonably correlate
to each other, results of many studies have proved that it is not
always the case. As it is clear, mRNAwill be destroyed after
translation into protein, but proteins will remain in the cell
until the end of its half-life. As a result, a CSC whose DCLK1
promoter has been hypermethylated and cannot express
DCLK1 anymore may still carry DCLK1 proteins that have
been built before hypermethylation. Several different studies
confirmed that the mRNA level of a gene does not necessarily
predict its protein level [68–71]. To this reason, the evaluation
of DCLK1 protein instead of DCLK1 mRNA may result in
more valuable information.
Moreover, the source of the markers in controls and pa-
tients should still be addressed in future studies. The question
is if they are CSC markers, why do they appear in normal
controls’ circulation? There are many possible explanations
to consider. It should not be neglected that although Lgr5
and DCLK1 are mentioned as the most colorectal CSC mark-
er, it does not mean that they are not expressed by any other
kind of cells. As an example, DCLK1 is mentioned as the
brain-specific protein [72] and Lgr5 is frequently mentioned
as gastrointestinal normal stem cell marker [36]. They might
also be expressed by other tissues that have not been investi-
gated yet, and they could enter the circulation for lots of un-
known reasons such as in stem cell circulation process [73]. In
addition, blood cells may themselves express these markers at
basic levels that need to be elucidated in future investigations.
On the other hand, a part of markers’ expression in patients is
related to other sources than CSCs. Fortunately, determining a
cutoff gives us the capability to compare the expression pat-
tern between controls and patients.
As a matter of fact, in order to determine the source of CSC
markers in blood circulation, sorting of the cells based on
multiple CSC markers is the most probable approach. In this
way, we could consider CD45−/DCLK1+/Lgr5+ cells as circu-
lating colorectal CSC. However, CSCs constitute a small frac-
tion of tumor cells, and from this amount [74], a very few
number of CSCs enter the blood circulation in order to com-
plete metastasis cascade and we only take 10 ml of blood as a
representative sample. As a result, we need a high-throughput
cell sorting method whose sensitivity is comparable to PCR.
Conclusion
Basically, we expect markers of the same category to move in
the same direction. In this regard, we predicted a similar ex-
pression pattern for Lgr5 and DCLK1 as the proposed CSC
markers. As expected, our data showed a significant level of
similarity between Lgr5 and DCLK1 expression pattern in
PB. However, some differences in expression pattern of
markers considering patients clinicopathologic findings was
observed. The most prominent difference was found in pa-
tients with and without the history of neoadjuvant therapy that
increase in mRNA expression of DCLK1 but not Lgr5 was
observed in patients with pre-operation chemoradiotherapy.
This difference could be simply attributed to the nature of
Lgr5 as it is both normal and CSC marker, whereas DCLK1
is considered as an exclusive colorectal CSC marker. Other
factors may also associate to the observed differences in the
expression of CSC markers that has been discussed in detail.
Our results also showed positive diagnostic and prognostic
role of Lgr5 and DCLK1 as potential CSC markers in CRC.
However, application of these markers in clinical implications
still needs more evaluation in a more comprehensive study
with bigger sample number.
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